Výsledky vyhledávání - "MESH: Maximum Tolerated Dose"

Discovery of a New Analgesic Peptide, Leptucin, from the Iranian Scorpion, Hemiscorpius lepturus

Autor: Jean-Marc Sabatier, Soroush Sardari, Sedigheh Bagheri-Ziari, Delavar Shahbazzadeh, Kamran Pooshang Bagheri

Publikováno v: Molecules
Molecules, MDPI, 2021, 26 (9), pp.2580. ⟨10.3390/molecules26092580⟩
Volume 26
Issue 9
Molecules, 2021, 26 (9), pp.2580. ⟨10.3390/molecules26092580⟩
Molecules, Vol 26, Iss 2580, p 2580 (2021)

International audience; Hemiscorpius lepturus scorpion stings do not induce considerable pain based on epidemiological surveys conducted in the southwest part of Iran. Accordingly, this study was aimed to identify the analgesic molecule in H. lepturu

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::670e938b01811fa520ec7c360c07c48d
https://doi.org/10.3390/molecules26092580

Zobrazit plný text záznamu

Plný text ve formátu HTML

Pertuzumab monotherapy after trastuzumab-based treatment and subsequent reintroduction of trastuzumab: activity and tolerability in patients with advanced human epidermal growth factor receptor 2-positive breast cancer

Autor: Stefania Salvagni, Javier Cortes, Joan Albanell, Joanna Dixon, Karen A. Gelmon, Teresa M Petrella, Pierfranco Conte, Giulia Bianchi, José Baselga, Ana Lluch, Maurizio Scaltriti, V. Servent, Luca Gianni, Pierre Fumoleau, Xavier Pivot, Graham Ross, Shailendra Verma, Tania Szado

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, 2012, 30 (14), pp.1594-600. ⟨10.1200/JCO.2011.37.4207⟩
Journal of Clinical Oncology, American Society of Clinical Oncology, 2012, 30 (14), pp.1594-600. ⟨10.1200/JCO.2011.37.4207⟩

Purpose The combination of pertuzumab and trastuzumab resulted in a clinical benefit rate (CBR) of 50% in patients with human epidermal growth factor receptor 2 (HER2) –positive breast cancer whose disease progressed during prior trastuzumab-based

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd26e9866e5bfdd2b47bef6bff3929f1
https://pubmed.ncbi.nlm.nih.gov/22393085

Zobrazit plný text záznamu

Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer

Autor: Cristina Oliva, M. John Kennedy, Gilles Romieu, Xavier Pivot, Michael F. Press, J. Maltzman, S. Stein, Stephen S. Johnston, L. O'Rourke, Henry L. Gomez, Mikhail Lichinitser, A. Florance, John Pippen, Alexey Manikhas, Saeed Sadeghi, Véronique Diéras, Mark D. Pegram

Publikováno v: Journal of Clinical Oncology
Journal of Clinical Oncology, American Society of Clinical Oncology, 2009, 27 (33), pp.5538-46. ⟨10.1200/JCO.2009.23.3734⟩

PurposeCross-talk between human epidermal growth factor receptors and hormone receptor pathways may cause endocrine resistance in breast cancer. This trial evaluated the effect of adding lapatinib, a dual tyrosine kinase inhibitor blocking epidermal

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::78ac01a09d5932d07b0882603d570e92
https://www.hal.inserm.fr/inserm-00484768

Zobrazit plný text záznamu

A randomized phase II trial assessing in advanced non-small cell lung cancer patients with stable disease after two courses of cisplatin-gemcitabine an early modification of chemotherapy doublet with paclitaxel-gemcitabine versus continuation of cisplatin-gemcitabine chemotherapy (GFPC 03-01 Study)

Autor: Romain Corre, Christos Chouaid, Pierre Fournel, J.-M. Vernejoux, Henri Berard, Benoit Marin, Alain Vergnenegre, Julie Tillon, Fabrice Barlesi, Hervé Le Caer

Publikováno v: Journal of Thoracic Oncology
Journal of Thoracic Oncology, 2009, 4 (3), pp.364-70. ⟨10.1097/JTO.0b013e318197f4ff⟩
Journal of Thoracic Oncology, Lippincott, Williams & Wilkins, 2009, 4 (3), pp.364-70. ⟨10.1097/JTO.0b013e318197f4ff⟩
ResearcherID

International audience; BACKGROUND: There is no consensus on the optimal treatment for patients with advanced non-small cell lung cancer and stable disease after cisplatin-based chemotherapy. The objective of the trial was to evaluate a switch to a d

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1022067f5697c449794385e9699903e
https://hal.sorbonne-universite.fr/hal-00596930

Zobrazit plný text záznamu

A multicenter phase II study of XRP6258 administered as a 1-h i.v. infusion every 3 weeks in taxane-resistant metastatic breast cancer patients

Autor: Xavier Pivot, P. Koralewski, G. Schwartsmann, A. Chan, A. Gonçalves, J. L. Hidalgo, S. Assadourian, J. P. Lotz

Publikováno v: Annals of Oncology
Annals of Oncology, Elsevier, 2008, 19 (9), pp.1547-52. ⟨10.1093/annonc/mdn171⟩

International audience; BACKGROUND: XRP6258 is a novel taxoid with a low affinity for P-glycoprotein. This multicenter phase II study assessed the activity of XRP6258 in the treatment of taxane-resistant metastatic breast cancer (MBC). PATIENTS AND M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b60b9e62a2e21b4f6c88a545b140fc7c
https://www.hal.inserm.fr/inserm-00483407

Zobrazit plný text záznamu

[Efficacy and safety of ixabepilone (BMS-247550), a novel epothilone B analogue]

Autor: Villanueva, Cristian, Dufresne, Armelle, Pivot, Xavier, Viel, Erika

Publikováno v: Bulletin du Cancer
Bulletin du Cancer, John Libbey Eurotext, 2008, 95 (2), pp.197-204. ⟨10.1684/bdc.2008.0577⟩

International audience; The epothilones are a new class of non-taxane tubulin polymerization agents obtained by natural fermentation of the myxobacteria Sorangium cellulosum. The cytotoxic activities of the epothilones, like those of the taxanes, hav

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::cd5440ec7c525eb4f6a46eec465d9d13
https://www.hal.inserm.fr/inserm-00484239

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání